Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENA-003
- Development stage
- Unknown
- Lead developer
- Enalare Therapeutics
- Modality
- Small Molecules
01
Overview
ENA-003 is a small molecule opioid receptor antagonist being developed by Enalare Therapeutics for the treatment of drug overdose-induced respiratory depression. The drug is designed to reverse or prevent the life-threatening suppression of breathing caused by opioids. Currently in Phase 2 clinical development, ENA-003 represents a potential therapeutic option for emergency intervention in opioid overdose scenarios, aiming to restore normal ventilatory function by blocking the effects of opioids at their receptor sites.
Beyond the preview
Go deeper on ENA-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENA-003.